HC Wainwright Reiterates “Buy” Rating for Liquidia (NASDAQ:LQDA)

Liquidia (NASDAQ:LQDA)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $29.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 91.80% from the company’s current price. HC Wainwright also issued estimates for Liquidia’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.25) EPS and FY2029 earnings at $0.51 EPS.

LQDA has been the topic of a number of other research reports. Wells Fargo & Company began coverage on Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a report on Thursday, January 9th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Liquidia has an average rating of “Buy” and an average target price of $26.63.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $15.12 on Thursday. The stock’s 50-day moving average is $14.79 and its two-hundred day moving average is $12.18. Liquidia has a 1-year low of $8.26 and a 1-year high of $16.99. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -9.28 and a beta of 0.07.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The company had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $4.60 million. Equities research analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Activity at Liquidia

In related news, General Counsel Russell Schundler sold 16,393 shares of the company’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the sale, the general counsel now directly owns 573,478 shares of the company’s stock, valued at $6,755,570.84. This represents a 2.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Roger Jeffs sold 22,343 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the completion of the sale, the chief executive officer now directly owns 1,019,177 shares of the company’s stock, valued at approximately $12,005,905.06. This trade represents a 2.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,245 shares of company stock valued at $843,326 in the last three months. 30.10% of the stock is currently owned by company insiders.

Institutional Trading of Liquidia

A number of hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its position in Liquidia by 17.5% during the 4th quarter. California State Teachers Retirement System now owns 51,928 shares of the company’s stock worth $611,000 after acquiring an additional 7,725 shares during the period. Toronto Dominion Bank purchased a new position in shares of Liquidia during the 4th quarter worth approximately $235,000. Alpine Global Management LLC raised its stake in shares of Liquidia by 50.0% during the 4th quarter. Alpine Global Management LLC now owns 150,000 shares of the company’s stock worth $1,764,000 after buying an additional 50,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Liquidia by 26.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 105,734 shares of the company’s stock valued at $1,243,000 after purchasing an additional 22,445 shares in the last quarter. Finally, Whitefort Capital Management LP increased its stake in Liquidia by 16.8% in the 4th quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock valued at $23,370,000 after purchasing an additional 285,220 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).